<DOC>
	<DOCNO>NCT01944319</DOCNO>
	<brief_summary>To evaluate clinical economical benefit meropenem dosage strategy base population pharmacokinetic ( PPK ) -pharmacodynamic ( PD ) model low respiratory tract infection patient .</brief_summary>
	<brief_title>Meropenem Dosage Strategy Based PPK Model</brief_title>
	<detailed_description>- Subjects : low respiratory tract infection patient - Study design : randomize control study.The patient study group accept meropenem therapy regimen decide software develop PPK-PD model . The patient control group accept meropenem therapy regimen decide attend physician . - Primary endpoint : clinical successful rate meropenem therapy . The clinical efficiency meropenem therapy evaluate one week later stop meropenem therapy . - Second endpoint : amount use antibiotic bacteriological successful rate .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<criteria>Sixty year old patient hospitalize Peking University Third Hospital communityacquired hospitalacquired low respiratory tract infection . Bacilli idolated low respiratory tract specimen within 48 hour prior study enrollment . The pathogen sensitive meropenem . Received broadspectrum antibiotic therapy le 24 hour , improvement antibiotic therapy pathogen resistant use antibiotic . Had document hypersensitivity carbapenems . More one pathogenic Gramnegative bacillus isolate low respiratory tract specimen . Positive HIV antibody titre . Had know suspect tuberculosis infection cause Grampositive cocci , viruses fungi baseline .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Infection ; Meropenem ; Pharmacokinetics ; Pharmacodynamics</keyword>
</DOC>